...
首页> 外文期刊>Cancer biology & therapy >PARP inhibitors are not all equal
【24h】

PARP inhibitors are not all equal

机译:PARP抑制剂并不完全相同

获取原文
获取原文并翻译 | 示例
           

摘要

To many investigators PARP1 is simply a substrate for caspase 3, and whose cleavage is thought indicative of apoptosis. However, in reality PARP1 plays a major role in the biology of the cell cycle and DNA repair. PARP1 binds to damaged DNA where it becomes enzy-matically activated and ADP ribosylates itself and other proteins. PARP facilitates DNA repair complex formation, e.g., with BRCA1/2, and the activation of the cell cycle regulatory enzymes ATM and ATR. PARP inhibitors as a single agent have only shown any degree of efficacy in breast and ovarian cancer patients who lack BRCA1/2 function. The present studies examined PARP1 inhibitor biology in a range of triple negative and non-triple negative breast cancer cell lines.
机译:对于许多研究者来说,PARP1只是caspase 3的底物,其裂解被认为是凋亡的指示。但是,实际上,PARP1在细胞周期生物学和DNA修复中起着重要作用。 PARP1与受损的DNA结合,在此处被酶激活,ADP自身和其他蛋白质被核糖基化。 PARP促进DNA修复复合物的形成,例如与BRCA1 / 2结合,并促进细胞周期调节酶ATM和ATR的激活。 PARP抑制剂作为单一药物仅在缺乏BRCA1 / 2功能的乳腺癌和卵巢癌患者中显示出任何程度的疗效。本研究在一系列三阴性和非三阴性乳腺癌细胞系中检查了PARP1抑制剂的生物学特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号